What is the true risk of a pharmacokinetic drug-drug interaction?

European Journal of Clinical Pharmacology

Volumn 63, Issue 10, 2007, Pages 897-899

  Fuhr, Uwe ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; GEMFIBROZIL; HYPERICUM PERFORATUM EXTRACT; MIBEFRADIL;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; EDITORIAL; HUMAN; PATIENT MONITORING; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RELIABILITY; RISK ASSESSMENT; SAFETY;

AREA UNDER CURVE; DRUG INTERACTIONS; HERB-DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY; RISK ASSESSMENT; THERAPEUTIC EQUIVALENCY;

EID: 34548564120     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0357-6     Document Type: Editorial

References (15)

1. Saari TI, Laine K, Bertilsson L, Neuvonen, PJ, Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol DOI 10.1007/s00228-007-0350-0
2. Andrén L, Andreasson Å, Eggertsen R. Interaction between a commercially available St John's Wort product (Movina®) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol DOI 10.1007/s00228-007-0345-x
3. von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1 infected adults Eur J Clin Pharmacol DOI 10.1007/s00228-007-0344-y
4. Flaherty JH, Perry HM 3rd, Lynchard GS, Morley JE (2000) Polypharmacy and hospitalization among older home care patients. J Gerontol A Biol Sci Med Sci 55(10):M554-M559 Oct 2000
5. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72(6):685-691 Dec 2002
6. Backman JT, Wang JS, Wen X, Kivisto KT, Neuvonen PJ (1999) Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. Clin Pharmacol Ther 66(4):401-407 Oct 1999
7. EMEA (2001) Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98) as of July 2001
8. EMEA (2006) Questions and Answers on the Bioavailability and Bioequivalence Guideline (EMEA/CHMP/EWP/40326/2006) as of July 2006
9. FDA (2003) Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Revision 1. March 2003
10. FDA (2001) Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. January 2001
11. Steinijans VW, Hartmann M, Huber R, Radtke HW (1991) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29(8):323-328 Aug 1991
12. EMEA (1997) Note for Guidance on the Investigation of Drug Interactions (EMEA/CHMP/EWP/560/95) as of December 1997
13. FDA (2006) Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling, November 1999; and draft version as of September 2006
14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK (2005) Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352(14):1425-1435 Apr 7 2005
15. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM (1995) Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15(5):678-682 May 1995